Routes of
administration Oral CAS Number 132980-16-6 ChemSpider 116274 | ATC code none PubChem CID 131575 Molar mass 177.242 g/mol | |
 | ||
Legal status In general: uncontrolled | ||
5-Methoxy-6-methyl-2-aminoindane (MMAI), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogen effects in humans. It has been sold as a designer drug and research chemical online since 2010.
MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline, and as a result it has been suggested that SSRAs like MMAI and 4-MTA could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).
References
MMAI Wikipedia(Text) CC BY-SA